Immunitybio Inc (IBRX) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate AbbVie's ability to sustain growth through immunology and neuroscience franchises while offsetting biosimilar pressure on HUMIRA, signaling continued earnings resilience for investors.

Key Takeaways

• Revenue $61.2B, 8.6% growth, record high.
• SKYRIZI $5B Q4, 31.9% growth, 45% psoriasis share.
• RINVOQ $2.4B Q4, 28.6% growth, mid‑teen RA share.
• Neuroscience sales $10.7B, Violet nearing blockbuster.
• 2026 outlook: $67B revenue, EPS $14.5, $18.5B free cash.

Pulse Analysis

AbbVie’s 2025 earnings underscore a strategic pivot from reliance on legacy assets toward high‑margin biologics. While HUMIRA’s U.S. sales fell sharply as biosimilars captured market share, the company leveraged its immunology platform—particularly SKYRIZI and RINVOQ—to not only replace lost revenue but also expand market share in psoriasis, IBD and rheumatoid arthritis. This diversification mitigated the $16 billion erosion risk and positioned AbbVie as a dominant player in IL‑23 and JAK‑inhibitor‑adjacent therapies, reinforcing investor confidence in its revenue engine.

The growth narrative is further amplified by AbbVie’s neuroscience franchise, where a $10.7 billion haul reflects robust uptake of migraine and psychiatric treatments, and the rapid ascent of Violet in Parkinson’s disease. The drug’s 33% sequential increase and expanding global coverage suggest a clear path to blockbuster status, adding a new revenue pillar beyond immunology. Coupled with a $5 billion pipeline spend targeting CAR‑T, siRNA and next‑generation antibodies, AbbVie is building a pipeline that can sustain double‑digit top‑line growth and protect margins against competitive pressures.

Looking ahead, AbbVie’s 2026 guidance of $67 billion revenue and $14.5 billion EPS hinges on continued expansion of SKYRIZI and RINVOQ, successful readouts for upcoming indications, and the commercial rollout of Violet. The three‑year patient‑access agreement with the U.S. government, which includes $100 billion in R&D commitments, adds a strategic layer of regulatory goodwill while preserving pricing flexibility. For analysts, the combination of strong free cash flow, disciplined capital allocation, and a diversified product mix makes AbbVie a compelling case study in biotech resilience amid an increasingly competitive biosimilar landscape.